Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, will announce its third quarter 2016 results on Thursday, 17 November 2016. A presentation by Targovax’s CEO, Øystein Soug, to investors, analysts and the press will take place in Oslo at 10:00 CET.
The results report and the presentation will be available at www.circio.com in the Investors section from 07:00 CET.
The presentation will take place at 10:00 CET at:
The presentation will also be webcast live and can be accessed through www.circio.com.
At 14:00 CET (08:00 EST) The company will host a telephone conference which will include a presentation of the results, following a Q&A session. CEO Øystein Soug will present the company. Call in details can be found below.
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
Access code: 23804707#
Please make sure to dial in at least 5-10 minutes ahead to complete your registration.
See attached list for more dial-in numbers.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Jan Petter Stiff – Crux Advisers (Norway)
Phone: +47 995 13 891
Julia Phillips/Simon Conway – FTI Consulting (International)
Phone: +44 20 3727 1000
Arming the patient’s immune system to fight cancer
Targovax (OSE: TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. The Company’s pipeline is created from two novel proprietary platforms, with three therapeutic candidates in clinical development covering six indications including mesothelioma, ovarian cancer, resected pancreatic cancer, and soft tissue sarcoma. Targovax’s strategy is to bring products to market directly in those indications where it already has Orphan drug status and to partner with pharmaceutical companies in larger disease areas with significant commercial potential.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.